The pharmacology results are shown in Fig. 3B. Firstly, in AM7577 AML-PDX model bearing FLT3-ITD mutation, which is known to be an oncogenic driver of this model as described previously1, narazaciclib at 100 mg/kg completely diminished the leukemic load in peripheral blood. The gene discussed is FLT3; the disease is acute myeloid leukemia.